Success Metrics

Active Trials
2(33%)

Phase Distribution

Ph phase_1
1
17%
Ph phase_2
5
83%

Phase Distribution

1

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
5(83.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Other(2)

Detailed Status

unknown2
Not yet recruiting2
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (16.7%)
Phase 25 (83.3%)

Trials by Status

recruiting117%
unknown233%
not_yet_recruiting233%
active_not_recruiting117%

Recent Activity

2 active trials
Showing 5 of 6
active_not_recruitingphase_2

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

NCT03141359
recruitingphase_1

Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC

NCT06494943
not_yet_recruitingphase_2

Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma

NCT05151588
unknownphase_2

Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC

NCT05469061
unknownphase_2

Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer

NCT04590625
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03141359Phase 2

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

Active Not Recruiting
NCT06494943Phase 1

Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC

Recruiting
NCT05151588Phase 2

Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma

Not Yet Recruiting
NCT05469061Phase 2

Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC

Unknown
NCT04590625Phase 2

Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer

Unknown
NCT04153734Phase 2

Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC

Not Yet Recruiting

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6